Stock Performance#
Grail Inc. (NASDAQ:GRAL) saw its shares jump by 6.2% on Wednesday after TD Cowen upgraded the stock from Hold to Buy. The new price target is set at $65.00, which is lower than the previous target of $114.00.
Recent Trial Setbacks#
This upgrade comes on the heels of a significant setback for the company in its NHS Galleri trial. The trial did not meet its primary goal, leading to a sharp decline in shares by 60%. Despite this, TD Cowen analyst Dan Brennan remains optimistic about the future of multi-cancer early detection tests.
Market Potential#
Brennan highlighted the potential of the multi-cancer early detection market, estimating it to be worth around $70 billion. He believes that advancements in this area could lead to a major shift in how cancers are detected, allowing for earlier diagnosis and potentially extending lives for many individuals.
Analyst Insights#
While some may view the trial results as a failure, Brennan's discussions with key opinion leaders in the field suggest a more favorable outlook. He noted that feedback from these experts supports the likelihood of FDA approval, with an estimated 50% chance of Medicare approval, which could positively impact the company's future.
The new price target of $65 indicates a potential upside of 37% from the stock's closing price of $47 before Wednesday's trading.